Who is this relevant for?
- Hospitals managing supply risk
- Distributors monitoring sourcing opportunities
A new meta-analysis published in Arthritis & Rheumatology confirms that the risk of hydroxychloroquine-associated retinopathy rises with duration and dose in patients with rheumatic diseases. The pooled analysis of 19 studies covering over 9,000 patients found a cumulative incidence of 0.1% at 5 years, 2.6% at 10 years, and 5.6% at 15 years.
Dose matters significantly. Patients receiving more than 5 mg/kg/day had a hazard ratio of 4.32 for retinopathy compared with those on lower doses. At 15 years, 13.8% of the higher-dose group developed retinopathy versus 2.7% on the standard dose. Duration also increased risk (OR 2.83 per 5-year increment).
Other risk factors include chronic kidney disease (HR 1.94), female sex (HR 3.78), and Asian ethnicity (HR 1.67). The study reinforces that HCQ remains a mainstay for SLE and RA, but operators should ensure dosing adheres to established guidelines and that screening programs are in place for long-term patients. For hospitals managing chronic therapy, this data supports tighter inventory control and protocol adjustments. Distributors may see shifts in demand as prescribers align with dose-dependent risk thresholds.